POLYVALENT VACCINE IN IL-2+GM-CSF LIPOSOMES FOR MELANOMA

IL-2 GM-CSF 脂质体中的多价疫苗用于治疗黑色素瘤

• 批准号: 6651998
• 负责人: JEAN-CLAUDE BYSTRYN
• 金额: $ 35.07万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-12 至 2004-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6651998
• 关键词: antitumor antibody; colony stimulating factor; guinea pigs; human subject; human therapy evaluation; interleukin 2; laboratory mouse; liposomes; melanoma; neoplasm /cancer immunotherapy; neoplasm /cancer vaccine; nonhuman therapy evaluation; patient oriented research; tumor antigens; vaccine development; western blottings

Our goal is to develop a potent adjuvant that can strongly, but safely, boost the immunogenicity of cancer vaccines. The proposal is based on recent observations that IL-2 and GM-CSF can individually increase the immunogenicity of vaccines, and that the adjuvant activity of each cytokine is markedly increased by co-encapsulating the cytokine into liposomes together with the vaccine. As each cytokine upregulates vaccine immunogenicity by different mechanisms, the combination of both cytokines should result in a particularly potent adjuvant. To test this hypothesis, we propose to conduct a randomized phase II trial to examine: 1) Whether IL-2+GM-CSF co-encapsulated into liposomes together with a melanoma vaccine can increase vaccine-induced cellular immune responses more strongly than either cytokine alone. Patients with resected AJCC stage III melanoma who are HLA-A2(+) will be randomized to treatment with a polyvalent, shed melanoma antigen vaccine encapsulated into lipsomes together with IL-2 or GM-CSF, or with both cytokines. The magnitude of vaccine-induced CD8+ T cell responses to A-2 restricted peptides derived from MAGE-3, MART-1, gp100, tyrosinase and TRP-2 will be measured by ELISPOT at baseline and at fixed intervals following immunization. 2) Whether IL-2+ GM-CSF lipisomes can enhance vaccine-induced antibody responses more strongly than either cytokine alone: Vaccine-induced antibody responses in the 3 groups of patients will be measured to individual melanoma antigens by Western immunoblotting. 3)The safety of this treatment/ Side effects will be followed by standard procedures. Major strengths of this proposal are that we have already demonstrated that IL-2 liposomes and GM-CSF liposomes are individually potent vaccine adjuvants in humans, that we have determined the optimal doses of each cytokine that maximally enhance vaccine-induced immune responses when encapsulated into lipsomes, that we have developed assays that are sufficiently sensitive to measure vaccine-induced CD8+ T cell and antibody responses to individual melanoma antigens, and that the vaccine contains multiple melanoma antigens so that the adjuvant activity of IL-2 + GM-CSF liposomes with different antigens can be evaluated. Successful completion of this work will provide a new method to increase the effectiveness of melanoma vaccines, and may lead to an improved treatment for the primary and secondary prevention of this cancer. More broadly, it may provide a general method of potentiating the immunogenicity of vaccines against other cancers and to infectious diseases.

我们的目标是开发一种有效的佐剂，可以强烈，但安全地提高癌症疫苗的免疫原性。 该提议是基于最近的观察，即IL-2和GM-CSF可以单独增加疫苗的免疫原性，并且通过将细胞因子与疫苗一起共包封到脂质体中，每种细胞因子的佐剂活性显著增加。 由于每种细胞因子通过不同的机制上调疫苗免疫原性，因此两种细胞因子的组合应产生特别有效的佐剂。 为了验证这一假设，我们建议进行随机II期试验以检查：1）与黑素瘤疫苗一起共包封到脂质体中的IL-2+GM-CSF是否可以比单独的细胞因子更强烈地增加疫苗诱导的细胞免疫应答。 患有切除的AJCC III期黑色素瘤且HLA-A2（+）的患者将随机接受多价脱落黑色素瘤抗原疫苗（与IL-2或GM-CSF一起封装在脂质体中）或与两种细胞因子一起治疗。 在基线和免疫后的固定时间间隔，通过ELISPOT测量疫苗诱导的CD 8 + T细胞对源自法师-3、MART-1、gp 100、酪氨酸酶和TRP-2的A-2限制性肽的应答的幅度。 2)IL-2+ GM-CSF脂质体是否可以比单独的细胞因子更强地增强疫苗诱导的抗体应答：将通过Western免疫印迹法测量3组患者中针对单个黑素瘤抗原的疫苗诱导的抗体应答。 3)将通过标准程序跟踪该治疗的安全性/副作用。该提议的主要优点在于，我们已经证明IL-2脂质体和GM-CSF脂质体是人体中单独有效的疫苗佐剂，我们已经确定了每种细胞因子的最佳剂量，其在包封到脂质体中时最大限度地增强疫苗诱导的免疫应答，我们已经开发了足够灵敏的检测方法来测量疫苗诱导的CD 8 + T细胞和抗体对单个黑素瘤抗原的应答，并且该疫苗含有多种黑素瘤抗原，从而可以评价具有不同抗原的IL-2 + GM-CSF脂质体的佐剂活性。 这项工作的成功完成将提供一种新的方法来提高黑色素瘤疫苗的有效性，并可能导致改善这种癌症的初级和二级预防治疗。 更广泛地说，它可以提供增强针对其他癌症和传染病的疫苗的免疫原性的一般方法。

项目成果

Melanoma vaccines: what we know so far.

黑色素瘤疫苗：到目前为止我们所知道的。

• 发表时间: 2005
• 期刊: Oncology (Williston Park, N.Y.)
• 作者: Bystryn,Jean-Claude;Reynolds,SandraR
• 通讯作者: Reynolds,SandraR

Vaccines for melanoma.

黑色素瘤疫苗。

• DOI: 10.1016/s0733-8635(02)00038-4
• 发表时间: 2002
• 期刊: Dermatologic clinics
• 影响因子: 2.4
• 作者: Bystryn,Jean-Claude

Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy?

黑色素瘤患者的细胞质黑色素瘤相关抗原（CYT-MAA）血清水平：免疫治疗反应的潜在标志物？

• DOI: 10.1002/ijc.21820
• 发表时间: 2006
• 期刊: International journal of cancer
• 影响因子: 6.4
• 作者: Reynolds,SandraR;Vergilis,IreneJ;Szarek,Michael;Ferrone,Soldano;Bystryn,Jean-Claude
• 通讯作者: Bystryn,Jean-Claude

Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma.

黑色素瘤患者血清中黑色素瘤相关抗原 CYT-MAA 和 HMW-MAA 的存在及其预后意义。

• DOI: 10.1111/j.0022-202x.2005.23798.x
• 发表时间: 2005
• 期刊: The Journal of investigative dermatology.
• 作者: Vergilis,IreneJ;Szarek,Michael;Ferrone,Soldano;Reynolds,SandraR
• 通讯作者: Reynolds,SandraR